GENFLEET-B (02595) has issued a corporate update detailing the timeline for sharing clinical study findings tied to its lead assets, GFH375 and GFH276. The company has scheduled an online investor conference for October 15, 2026, during which it will present initial data from a study assessing GFH375, a KRAS G12D inhibitor, in combination with cetuximab for the treatment of solid tumors harboring KRAS G12D mutations.
GENFLEET's overseas collaboration partner, Verastem Oncology, is set to host its own virtual investor briefing on October 14, 2026, to discuss the progress of the international clinical development program for GFH375, also referred to as VS-7375. In parallel, preliminary clinical results from a monotherapy study of GFH276, a Pan RAS inhibitor, in patients with RAS-mutant solid tumors, have been accepted for presentation as a late-breaking abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) annual meeting, scheduled to take place in Madrid.
To provide deeper context on these findings, GENFLEET will hold an additional online investor call on October 25, 2026, offering a thorough review of the oral presentation data for GFH276. The company's broader alliance with Verastem covers a licensing and early-stage co-development framework for three investigational products designed to target RAS/MAPK-driven cancers. Under this agreement, Verastem holds an exclusive option to secure individual licenses for each of these three candidates once predefined milestones from Phase I clinical trials are successfully achieved.
In December 2023, Verastem selected GFH375/VS-7375 as the lead program under this collaboration, and subsequently exercised its option to license GFH375 in January 2025, marking the first license to emerge from the partnership. These licenses grant Verastem the rights to develop and commercialize the licensed products outside of mainland China, while GENFLEET retains full rights within the Chinese market. GFH276 stands out as a mechanistically distinct oral small-molecule pan-RAS (ON) inhibitor, employing a unique tri-complex mechanism of action (CypA-GFH276-RAS) that enables more potent suppression across a broad spectrum of activated wild-type and mutant RAS protein isoforms, including the most prevalent KRAS mutations (such as G12C, G12D, and G12V) as well as NRAS and HRAS variants.
Comments